Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling
Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling
About this item
Full title
Author / Creator
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Objectives
Approximately 25% of Americans suffer from laryngopharyngeal reflux (LPR), a disease for which no effective medical therapy exists. Pepsin is a predominant source of damage during LPR and a key therapeutic target. Fosamprenavir (FOS) inhibits pepsin and prevents damage in an LPR mouse model. Inhaled FOS protects at a lower dose than o...
Alternative Titles
Full title
Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_10ed8a7c18e849f5abc41f2314e40880
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_10ed8a7c18e849f5abc41f2314e40880
Other Identifiers
ISSN
2378-8038
E-ISSN
2378-8038
DOI
10.1002/lio2.1219
